• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Resistance to Targeted Therapies in Lymphomas

Resistance to Targeted Therapies in Lymphomas

Hardcover

Series: Resistance to Targeted Anti-Cancer Therapeutics, Book 21

Medical Reference

ISBN10: 3030244237
ISBN13: 9783030244231
Publisher: Springer Nature
Published: Sep 30 2019
Pages: 210
Weight: 1.11
Height: 0.56 Width: 6.14 Depth: 9.21
Language: English

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called target therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy.

Also in

Medical Reference